Investor Stock List
Ranked #960 of 8,699 institutional investors

Frazier Life Sciences Management, L.P.

Palo Alto, CA

$3.93B
US stock portfolio at live prices · today +$35.4M (+0.91%)
Market closed. Prices as of Nov 20, 7:41 AM ET
Value at quarter end (Q3 2026)
$4.03B
Change from Q2 2026
−$561.5M (−12.23%)
Positions
40 · 5 new, 2 sold out
Filed
Nov 16, 2026

Not counted in the ranking: none$523M of holdings we could not match to a US listing are included at their reported quarter-end value.

Holdings

Q3 2026 13F, live prices
MIRM 18.7%ERAS 10.7%MBX 9.04%ARQT 6.82%MAZE 4.36%
StockSharesValue, live% of portfoliovs Q2 2026
MIRM Mirum Pharmaceuticals, Inc.7,679,684$733M18.7%Unchanged
ERAS Erasca, Inc.29,475,188$419M10.7%Added +18%
MBX MBX Biosciences, Inc.6,652,013$355M9.04%Unchanged
ARQT Arcutis Biotherapeutics, Inc.9,874,511$268M6.82%Unchanged
MAZE Maze Therapeutics, Inc.5,282,915$171M4.36%Added +5%
TRVI Trevi Therapeutics, Inc.9,539,147$131M3.33%Reduced −4%
PVLA Palvella Therapeutics, Inc.882,400$129M3.27%Unchanged
KRYS Krystal Biotech, Inc.391,319$124M3.14%Reduced −19%
ATTO Attovia Therapeutics, Inc.7,046,271$110M2.79%New
BRVE Braveheart Bio, Inc.5,267,321$102M2.58%New
IRON Disc Medicine, Inc.934,852$71.2M1.81%Reduced −31%
PBLS Parabilis Medicines, Inc.2,330,750$64.4M1.64%Added +21%
PHAT Phathom Pharmaceuticals, Inc.12,466,489$63.3M1.61%Unchanged
MNKD MannKind Corporation15,755,491$62.2M1.58%Added +139%
DYN Dyne Therapeutics, Inc.3,853,082$61.8M1.57%Added +22%
TARS Tarsus Pharmaceuticals, Inc.720,338$55.9M1.42%Reduced −1%
VOR Vor Biopharma Inc.2,743,939$50.8M1.29%Added +8%
AURA Aura Biosciences, Inc.7,100,000$49.6M1.26%Unchanged
QUIT Achieve Life Sciences, Inc.7,614,836$44.7M1.14%Unchanged
ZLAB Zai Lab Limited1,902,320$41.7M1.06%Unchanged
ACRS Aclaris Therapeutics, Inc.8,729,516$30.6M0.78%Added +77%
BCRX BioCryst Pharmaceuticals, Inc.4,009,240$29.3M0.75%Unchanged
ACAD Acadia Pharmaceuticals Inc.1,438,198$25.3M0.64%Unchanged
CLDX Celldex Therapeutics, Inc.900,080$25.2M0.64%New
IMCR Immunocore Holdings plc829,752$22.1M0.56%Added +71%
EOLS Evolus, Inc.2,630,665$18.4M0.47%Unchanged
STTK Shattuck Labs, Inc.3,750,000$17.1M0.43%Unchanged
DSGN Design Therapeutics, Inc.1,809,854$16.9M0.43%Unchanged
RLAY Relay Therapeutics, Inc.1,015,693$16.2M0.41%Unchanged
SRPT Sarepta Therapeutics, Inc.1,069,959$15.2M0.39%New
ALLO Allogene Therapeutics, Inc.22,446,668$15.0M0.38%Unchanged
LXEO Lexeo Therapeutics, Inc.4,824,725$14.2M0.36%Unchanged
KLRA Kailera Therapeutics, Inc.1,200,000$13.9M0.35%Added +9%
VALN Valneva SE2,291,666$12.3M0.31%Unchanged
GLUE Monte Rosa Therapeutics, Inc.1,000,000$8.9M0.23%Unchanged
SVRA Savara Inc.1,113,752$5.8M0.15%Reduced −89%
ORIC ORIC Pharmaceuticals, Inc.751,672$5.8M0.15%New
AUTL Autolus Therapeutics plc4,447,910$4.4M0.11%Unchanged
XLO Xilio Therapeutics, Inc.422,505$3.2M<0.1%Unchanged
IBIO iBio, Inc.1,953,467$1.6M<0.1%Unchanged

Sold out in Q3 2026

StockShares held at Q2 2026Worth today
BBIO BridgeBio Pharma, Inc.1,548,139$121M
CYTK Cytokinetics, Incorporated1,159,879$59.7M